90-day Pod-type Etonogestrel/Ethinyl Estradiol/QGriffithsin (QGRFT) Intravaginal Ring [EEQ IVR]

Status

Ongoing

Phase

Pre-clinical

Principal Investigator(s)

TELESHOVA, NATALIA

Objective

A 90-day pod-type MPT IVR for pregnancy and HIV prevention that could reduce both the emergence of ARV-resistant HIV and the concern of potential increased risk of HIV transmission associated with use of progestin-only products.

Prevention Option(s)

Microbicides

Arms and Assigned Interventions

Mode of Delivery

Ring

Products

Q-GRFT

Trial Sponsors

NIAID

Product Developers

Oak Crest Institute of Science; Population Council

April 2020

March 2025

You are here

90-day Pod-type Etonogestrel/Ethinyl Estradiol/QGriffithsin (QGRFT) Intravaginal Ring [EEQ IVR]